$GILD: Gilead Sciences Reports Q3 2026: Base Sales Up 16%, Non-GAAP EPS Rises

$GILD

$GILD – Gilead Sciences Reports Q3 2026: Base Sales Up 16%, Non-GAAP EPS Rises to $2.55

GILEAD SCIENCES, INC.

2026-10-29 00:00:00 UTC · SEC_8K · All $GILD

?? Positive AI Sentiment (+2.5 / 10)

Product sales excluding Veklury rose 16% YoY to $8.2 billion, led by Biktarvy sales up 10% to $4.1 billion.
GAAP diluted EPS declined to $1.94 vs $2.43 in prior year, while non-GAAP EPS increased to $2.55 from $2.47.
Q3 gross margin expanded to 81.0% compared to 78.6% in Q3 2025.